Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
448.40 USD | +1.45% |
|
-2.53% | +11.35% |
Jun. 17 | RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating | MT |
Jun. 17 | Saudi Arabia Signs Multiple Healthcare Deals, Partnerships at BIO 2025 | MT |
Capitalization | 115B 100B 94.32B 85.78B 158B 10,001B 178B 1,113B 430B 4,556B 432B 423B 16,782B | P/E ratio 2025 * |
29.8x | P/E ratio 2026 * | 25.5x |
---|---|---|---|---|---|
Enterprise value | 106B 92.46B 86.86B 78.99B 146B 9,210B 164B 1,025B 396B 4,196B 398B 389B 15,454B | EV / Sales 2025 * |
8.91x | EV / Sales 2026 * | 7.54x |
Free-Float |
99.04% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
1 day | +1.45% | ||
1 week | -2.53% | ||
Current month | +1.44% | ||
1 month | +1.76% | ||
3 months | -12.51% | ||
6 months | +13.05% | ||
Current year | +11.35% |
1 week | 440 | ![]() | 457.23 |
1 month | 427.43 | ![]() | 460.33 |
Current year | 397.24 | ![]() | 519.68 |
1 year | 377.85 | ![]() | 519.88 |
3 years | 265.98 | ![]() | 519.88 |
5 years | 176.36 | ![]() | 519.88 |
10 years | 71.46 | ![]() | 519.88 |
Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 2020-03-31 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 2019-04-09 |
Chief Tech/Sci/R&D Officer | - | - |
Director | Title | Age | Since |
---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 65 | 1997-12-31 |
Jeffrey Leiden
CHM | Chairman | 69 | 2012-04-30 |
Sangeeta Bhatia
BRD | Director/Board Member | 56 | 2015-06-17 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+1.45% | -2.53% | -4.04% | +70.44% | 115B | ||
-0.78% | -2.92% | -11.94% | +169.86% | 705B | ||
-1.08% | -2.92% | +3.49% | -11.05% | 363B | ||
+1.22% | -5.48% | -50.22% | +30.75% | 331B | ||
+0.01% | -3.14% | +8.25% | +34.14% | 328B | ||
+0.35% | -3.67% | +4.88% | -14.29% | 254B | ||
+0.25% | -1.85% | +2.21% | +20.55% | 228B | ||
+0.04% | -3.25% | -15.01% | +6.33% | 220B | ||
+1.29% | -1.28% | -38.05% | -6.30% | 199B | ||
-0.19% | -2.58% | -5.35% | +23.39% | 156B | ||
Average | +0.26% | -3.16% | -10.58% | +32.38% | 289.86B | |
Weighted average by Cap. | +0.01% | -3.07% | -10.87% | +51.75% |
2025 * | 2026 * | |
---|---|---|
Net sales | 11.91B 10.38B 9.75B 8.87B 16.36B 1,034B 18.45B 115B 44.43B 471B 44.68B 43.73B 1,735B | 13.22B 11.53B 10.83B 9.85B 18.17B 1,149B 20.49B 128B 49.34B 523B 49.63B 48.57B 1,927B |
Net income | 3.89B 3.4B 3.19B 2.9B 5.35B 338B 6.03B 37.63B 14.53B 154B 14.61B 14.3B 568B | 4.57B 3.99B 3.75B 3.41B 6.28B 397B 7.09B 44.21B 17.07B 181B 17.17B 16.8B 667B |
Net Debt | -9.12B -7.95B -7.47B -6.79B -12.52B -792B -14.12B -88.1B -34.01B -361B -34.21B -33.48B -1,329B | -15.49B -13.51B -12.69B -11.54B -21.28B -1,345B -24B -150B -57.79B -613B -58.13B -56.88B -2,257B |
More financial data
* Estimated data
Employees
6,100
Sector
Pharmaceuticals
Calendar
Date | Price | Change | Volume |
---|---|---|---|
25-06-18 | 448.40 $ | +1.45% | 1,380,456 |
25-06-17 | 441.99 $ | -1.98% | 1,363,520 |
25-06-16 | 450.91 $ | -1.00% | 1,030,124 |
25-06-13 | 455.45 $ | -1.00% | 1,021,563 |
25-06-12 | 460.06 $ | +1.68% | 1,074,625 |
Delayed Quote Nasdaq, June 18, 2025 at 04:00 pm EDT
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
448.40USD
Average target price
499.87USD
Spread / Average Target
+11.48%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions